Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood thinner showdown: which drug best prevents Post-Delivery clots?

NCT ID NCT01588171

Prevention Sponsor: Hawler Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study compared two blood-thinning drugs, Bemiparin and Enoxaparin, to prevent venous thromboembolism (dangerous blood clots) in 7020 women after vaginal or cesarean delivery. All participants had risk factors for clots and received daily injections for up to 7 days after giving birth. The goal was to see which drug worked better and had fewer side effects like bleeding or bruising.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Bemiparin (a blood thinner) and Enoxaparin (a blood thinner)
What this could lead to
If successful, this could show that Bemiparin is as good as or better than Enoxaparin at preventing blood clots after childbirth, offering another safe option for new mothers.
What could go wrong
This trial is completed, but results may not apply to all women. Both drugs carry risks like bleeding or bruising. The study did not test long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

7,020 people

The number who actually took part.

Start date

May 2012

Finished

Nov 2013

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

15 to 48 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Presence of risk factors for venous thromboembolism * Any parity * Mode of delivery:vaginal, Emergency and Elective Caesarean section * No any contraindications for Heparin Exclusion Criteria: * Active antenatal or postpartum vaginal bleeding. * Placenta previa * Thrombocytopenia * Sever renal or liver diseases * Uncontrolled sever hypertension * Any patient who is already on Heparin during pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Venous thromboembolic diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pulmonary embolism Venous Thrombosis venous thromboembolism prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Venous thromboembolic diseases

Contacts and locations

Locations

  • Hawler medical university

    Erbil, Kurdistan Region, 383-65, Iraq